

Grant approval for the study 'Augmentation with levodopa/ carbidopa to ameliorate negative and cognitive symptoms in schizophrenia'.

Schizophrenia is characterized by positive (presence of delusions and hallucinations), negative (flattening of affect, poverty of speech and thought), and cognitive (reduced abilities for learning and memory) symptoms. The currently used antipsychotics are notably effective in reducing the positive symptoms, but are significantly less effective in treating the negative and cognitive symptoms of schizophrenia. The purpose of this study is to investigate if augmentation of antipsychotic medication with levodopa/ carbidopa helps to ameliorate the negative and cognitive symptoms, which are found to be the most invalidating in patients who suffer from schizophrenia. The FondsNutsOhra has decided to sponsor this research of the group of Steven Kushner, in particular of Christian Bouwkamp, with a grant of €25.000.